Fly News Breaks for March 2, 2020
Mar 2, 2020 | 08:30 EDT
As previously reported, Wedbush analyst David Nierengarten initiated coverage of Beam Therapeutics with an Outperform rating and $32 price target. The analyst believes shares are "undervalued" based on his positive long-term outlook on the company's differentiated and potentially best-in-class gene editing platform, base editing, which is able to generate highly efficient and predictable single base pair changes in genomic DNA in order to correct genetic disease.
News For BEAM From the Last 2 Days
There are no results for your query BEAM